0001493152-23-020131.txt : 20230605 0001493152-23-020131.hdr.sgml : 20230605 20230605170820 ACCESSION NUMBER: 0001493152-23-020131 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230601 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230605 DATE AS OF CHANGE: 20230605 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardion Health Sciences, Inc. CENTRAL INDEX KEY: 0001642375 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474428421 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38861 FILM NUMBER: 23993671 BUSINESS ADDRESS: STREET 1: 2925 RICHMOND AVENUE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 BUSINESS PHONE: (800) 873-5141 MAIL ADDRESS: STREET 1: 2925 RICHMOND AVENUE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 FORMER COMPANY: FORMER CONFORMED NAME: Guardion Health Sciences, LLC DATE OF NAME CHANGE: 20150513 8-K 1 form8-k.htm
0001642375 false 0001642375 2023-06-01 2023-06-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 1, 2023

 

GUARDION HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38861   47-4428421

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

2925 Richmond Avenue, Suite 1200

Houston, Texas 77098

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (800) 873-5141

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   GHSI   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 1, 2023, Guardion Health Sciences, Inc. (the “Company”) entered into a Bonus Agreement with its Chief Commercial Officer, Craig Sheehan (the “2023 Bonus Agreement”). Pursuant to the 2023 Bonus Agreement, Mr. Sheehan will be eligible to receive a bonus of up to $200,000 during 2023 (the “2023 Bonus”). Mr. Sheehan will be paid the first tranche of the 2023 Bonus in the amount of $50,000 on July 15, 2023 and will be paid the remaining portion of the 2023 Bonus on the earlier of December 31, 2023 or within thirty (30) days following the closing date of a change in control of the Company, or a sale of the Company’s Viactiv brand and/or Activ Nutritional, LLC, a wholly-owned subsidiary of the Company, provided, in each case, that he (i) remains employed as a full-time employee of the Company and in good standing through the applicable payment (unless the Company terminates his employment without cause prior to such date), and (ii) has satisfied all of the terms of the 2023 Bonus Agreement and his employment agreement with the Company dated June 1, 2021.

 

The foregoing description of the 2023 Bonus Agreement does not purport to be complete and is subject to, and qualified in its entirety by, reference to the full text of the 2023 Bonus Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Exhibit
10.1+   Bonus Agreement by and between the Company and Craig Sheehan dated June 1, 2023
104   Cover Page Interactive Data File (embedded within the XBRL document)

 

+ Indicates a management contract or any compensatory plan, contract or arrangement.

 

-2-
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GUARDION HEALTH SCIENCES, INC.
Date: June 5, 2023    
  By: /s/ Bret Scholtes
  Name: Bret Scholtes
  Title: President and Chief Executive Officer

 

-3-

 

 EX-10.1 2 ex10-1.htm

 

Exhibit 10.1

 

June 1, 2023

 

Craig Sheehan

 

 

 

Re: 2023 Bonus Agreement

 

Dear Mr. Sheehan:

 

Guardion Health Sciences, Inc. (the “Company”) wishes to retain the benefits of your experience, expertise and assistance prior to a potential sale of the Viactiv® brand/Activ Nutritional, LLC entity, or “Change of Control”, as defined in the Guardion Health Sciences, Inc. 2018 Omnibus Equity Incentive Plan and to encourage you to actively support the process to obtain the maximum sales price of the Company or of the Viactiv product line. Accordingly, the Company is pleased to offer you this 2023 Bonus Agreement (the “Agreement”), which, when signed by you and returned to me, will provide you with financial incentives to maintain growth of the Company’s revenue and actively facilitate a successful transaction.

 

The terms of this Agreement are as follows:

 

1. 2023 Bonus. Subject to the terms and conditions of this Agreement, you will become eligible to receive a bonus of up to $200,000 (your “2023 Bonus”). You will be paid $50,000 of the 2023 Bonus (the “First Tranche”) on July 15, 2023, provided that you satisfy the eligibility and vesting requirements set forth in Section 2. The remaining $150,000 of the 2023 Bonus (the “Second Tranche”) will be paid on the earlier of December 31, 2023 or within thirty (30) days following the closing date of a sale of the Viactiv brand/Activ Nutritional, LLC entity.

 

2. Eligibility and Vesting Requirements.

 

(a) To receive the First Tranche and/or the Second Tranche of your 2023 Bonus, as applicable, you must (i) continuously be a full-time employee of the Company or any of its affiliates in good standing through the applicable payment of the First and/or Second Tranche of your 2023 Bonus, unless the Company terminates your employment without Cause (as such term is defined in your Employment Agreement) prior to the applicable payment date, and (ii) have fulfilled all of your commitments under this Agreement and in Section 7 of your Employment Agreement (as determined in the reasonable discretion of the Company) as of the applicable payment date of the First Tranche and Second Tranche.

 

-1-
 

 

(b) In connection with any Change of Control, as a condition to receiving any payment under this Agreement, you will, if requested by the Company, execute and deliver to the Company and/or any subsidiaries of the Company (the “Covered Parties”) or an acquiror (as applicable) (A) a release of the Covered Parties in a form prescribed by the Company, for acts, omissions or occurrences of the Company prior to such Change of Control, including those arising under this Agreement and your employment agreement with the Company and (B) any other agreement including nondisclosure, nonsolicitation, noncompetition, intellectual property rights or other restrictive covenants, or representations as to your knowledge regarding the Covered Parties or their business(es)), requested by the Company and/or an acquirer in connection with such Change of Control or sale of the Viactiv brand/Activ Nutritional, LLC entity. You will be granted a reasonable opportunity to negotiate the terms of any such document or agreement; however, in order to receive the payment, you must execute, deliver, and not revoke the release and enter into any such document or agreement in the form as ultimately required by the Company and/or an acquiror (subject to this paragraph) prior to the closing date of the Change of Control.

 

(c) Forfeiture.

 

i. You will forfeit your 2023 Bonus, including rights to receive any payment (i.e., past or future) with respect thereto, upon (A) your violation of any confidentiality, noncompetition, nonsolicitation, intellectual property rights or nondisclosure covenant set forth in any written agreement between you and the Company, (B) the termination of your employment by the Company for Cause, or you resign from employment prior to the date of the First Tranche and/or Second Tranche. Notwithstanding anything in this Section 2(c), the board of directors of the Company may, in its sole discretion, waive the forfeiture of any or all your 2023 Bonus upon your termination of continuous service or other forfeiture trigger set forth herein. Any such waiver must be in writing, explicitly reference this Section 2(c) and such waiver of a forfeiture requirement must be permissible, in all respects, under Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”).

 

ii. If you violate any of the covenants or agreements set forth in Section 7 of your Employment Agreement or any other material agreement with the Company, then you will not be eligible to receive the 2023 Bonus and, in addition, the Company will be entitled to exercise all remedies available under law or equity, including injunctive relief, and damages.

 

3. Confidentiality. In consideration for the payments and agreements described in this Agreement, you agree that, except as required in the performance of your duties on behalf of the Company or its affiliates, or to the extent otherwise required by law, you will not disclose to any party information related to the existence and/or contents of this Agreement, or information relating to the existence or terms of any sale transaction or Change of Control including, without limitation, price, parties, arrangements, schedules and all related information pertinent to the solicitation, presentation and closure of a transaction, or the fact that the Company would consider a future Change of Control. However, you may disclose the terms of this Agreement to your spouse or to your legal or financial adviser, provided that you take all reasonable measures to assure that they do not disclose the terms of this Agreement to another third party except as otherwise required by law.

 

-2-
 

 

4. Other Material Terms.

 

(a) Negotiation of a Change of Control. It is agreed and understood that at all times the Company will have the right to approve or disapprove of any prospective acquirer or investor, or the terms and conditions of any proposed Change of Control, and that the Company will have no obligation to enter into any Change of Control.

 

(b) Discharge of Obligations. Any payment made by the Company in good faith in accordance with the provisions of this Agreement shall fully discharge the Company from all further obligations with respect to such payment and this Agreement.

 

(c) Offset for Amounts Owed by You. If at any time when payments are to be made in accordance with the terms and conditions of this Agreement, you are indebted to or otherwise owe money to the Company or its affiliates, then the payments to be made to you may, at the Company’s discretion, be reduced by the amount of such indebtedness or other amount owed. An election by the Company not to reduce such payments shall not constitute a waiver by the Company or affiliate of its claim for such repayment to the extent permissible under Code Section 409A.

 

(d) Golden Parachute Limitation. The Company intends that the benefits provided under this Plan will not constitute an “excess parachute payment” under Code Section 280G. Notwithstanding any provision of this Agreement to the contrary, if any benefit to be paid under this Agreement (together with any benefit to be paid to you under any other agreement, plan or arrangement) would be an excess parachute payment, but for the application of this sentence, then the payments and benefits to be paid or provided under this Agreement shall be reduced to the minimum extent necessary (but in no event less than zero) so that no portion of any such payment or benefit, as so reduced, constitutes an excess parachute payment.

 

5. Miscellaneous.

 

(a) Assignment. The Company may assign any or all of its rights and obligations under this Agreement to any successor or affiliate of the Company, if such successor or affiliate agrees to assume all the obligations of the Company hereunder. You hereby consent to any such assignment and assumption. Your rights and obligations under this Agreement are not transferrable other than by will or the laws of descent and distribution, and may be realized during your lifetime only by you or your guardian or legal representative.

 

(b) Taxes. The Company may withhold from any amounts payable under this Agreement all taxes that the Company reasonably determines to be required pursuant to any law, regulation, or ruling. However, it is your obligation to pay all required taxes on any amounts provided under this Agreement, regardless of whether withholding is required. Notwithstanding any other provision of this Agreement, the Company does not make any guarantee of tax consequences with respect to this Agreement or any benefits or payments provided for herein.

 

-3-
 

 

(c) 409A Compliance. It is intended that any amounts payable under this Agreement shall comply with the provisions of Code Section 409A and the Treasury regulations relating thereto including, without limitation, the provisions and requirements of Treasury Regulations section 1.409A-3(i)(5)(iv), so as not to subject you to the payment of any interest or tax penalty that may be imposed under Code Section 409A. Further, for purposes of the limitations on nonqualified deferred compensation under Code Section 409A, each payment of compensation under this Agreement shall be treated as a separate payment of compensation for purposes of applying the exclusion for short-term deferral amounts. In furtherance of this interest, to the extent that any regulations or other guidance issued under Code Section 409A after the date of this Agreement would result in payment of interest or tax penalty under Code Section 409A, the Company and you agree to amend this Agreement in order to bring this Agreement into compliance with the exemption provisions of Code Section 409A. In no event shall the Company, its affiliates, successors, shareholders, employees, officers or agents have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Code Section 409A.

 

(d) Entire Agreement; Modification. This Agreement sets forth the entire understanding of you and the Company regarding payment of any incentive, transaction bonus, retention bonus or other change of control bonus amounts, or other similar cash proceeds due or payable upon or in connection with a Change of Control or otherwise, and supersedes all prior oral or written agreements between you and the Company regarding the payment of any such amounts. Nothing in this Agreement shall supersede or otherwise negate any post-employment confidentiality, nondisclosure, nonsolicitation, noninterference, intellectual property or noncompetition obligations imposed by any other agreement between you and any of the Covered Parties. This Agreement may not be modified except by written agreement by you and the Company.

 

(e) Notices. All correspondences by the parties pursuant to this Agreement will be provided to the other party at the address listed on the first page of this Agreement, or as otherwise supplemented by a party hereto pursuant to notice.

 

(f) General Creditor Status. The Company’s obligations under this Agreement shall be unsecured and unfunded obligations, and you shall be a general creditor of the Company.

 

(g) Third Party Beneficiaries. The terms and provisions of this Agreement are intended solely for you, the Company and its affiliates, and each of their respective successors or permitted assigns, and it is not the intention of the parties hereto to confer third-party beneficiary rights upon any other person or entity.

 

(h) Waiver. Any delay or omission by a party in exercising its rights under this Agreement, or failure to insist upon strict compliance with any term, covenant, or condition of this Agreement, will not be deemed a waiver of such term, covenant, condition or right, nor will any waiver or relinquishment of any right or power under this Agreement at any time or times be deemed a waiver or relinquishment of such right or power at any other time or times. No waiver will be effective unless it is expressly set forth in a written instrument executed by the waiving party and any such waiver will have no effect except in the specific instance in which it is given.

 

(i) No Strict Construction. No rule of strict construction will be applied against the Company in the interpretation of any of the terms of this Agreement.

 

-4-
 

 

(j) Ownership Rights. You will not have any distribution, voting or other rights of equity holder(s) of the Company by reason of this Agreement.

 

(k) No Employment Contract. You understand and acknowledge that this Agreement does not constitute a contract of employment and does not establish or imply that your employment will continue for any period of time. Except as otherwise may be set forth in any written employment agreement between you and the Company, you remain an at-will employee, such that either you or the Company may terminate your employment at any time, with or without cause or prior notice.

 

(l) Survival. Provisions of this Agreement which by their nature are intended to survive termination or expiration of this Agreement will survive any termination or expiration of this Agreement.

 

(m) Governing Law. All matters arising out of, or relating to, this Agreement, including, without limitation, its validity, interpretation, construction, performance and enforcement, shall be governed by the laws of the state of California, determined without regard to its conflicts of law principles.

 

(n) JURY TRIAL WAIVER. TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ALL RIGHT OF TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM RELATING TO, ARISING OUT OF, OR IN CONNECTION WITH, THIS AGREEMENT, OR ANY MATTER ARISING HEREUNDER. SUCH WAIVER IS A MATERIAL INDUCEMENT TO THE COMPANY’S ENTERING INTO THIS AGREEMENT.

 

(o) Counterpart; Electronic Signatures. This Agreement may be executed in counterparts, all of which shall together constitute an effective agreement. A facsimile or other electronic transmission of signatures to this Agreement shall be binding on the parties hereto.

 

(Signature page follows)

 

-5-
 

 

The Company believes that this Agreement provides you with financial incentives to remain employed with the Company and committed to the Company’s success. Please indicate your acceptance by signing below and returning it to me. This Agreement shall be effective as of the last date indicated below.

 

Sincerely,

 

Guardion Health Sciences, Inc.

 

By: /s/ Bret Scholtes  
Name: Bret Scholtes  
Title: President and Chief Executive Officer  

 

I acknowledge and agree to the terms and conditions set forth in this Agreement:

 

 

By: /s/ Craig Sheehan  
Print name: Craig Sheehan  
Date: June 1, 2023  

 

-6-

 EX-101.SCH 3 ghsi-20230601.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ghsi-20230601_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ghsi-20230601_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Jun. 01, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 01, 2023
Entity File Number 001-38861
Entity Registrant Name GUARDION HEALTH SCIENCES, INC.
Entity Central Index Key 0001642375
Entity Tax Identification Number 47-4428421
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2925 Richmond Avenue
Entity Address, Address Line Two Suite 1200
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77098
City Area Code (800)
Local Phone Number 873-5141
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol GHSI
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001642375 2023-06-01 2023-06-01 iso4217:USD shares iso4217:USD shares 0001642375 false 8-K 2023-06-01 GUARDION HEALTH SCIENCES, INC. DE 001-38861 47-4428421 2925 Richmond Avenue Suite 1200 Houston TX 77098 (800) 873-5141 false false false false Common Stock, par value $0.001 per share GHSI NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://guardionhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex10-1.htm ghsi-20230601.xsd ghsi-20230601_lab.xml ghsi-20230601_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "ghsi-20230601_lab.xml" ] }, "presentationLink": { "local": [ "ghsi-20230601_pre.xml" ] }, "schema": { "local": [ "ghsi-20230601.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "GHSI", "nsuri": "http://guardionhealth.com/20230601", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-06-01to2023-06-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://guardionhealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-06-01to2023-06-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001493152-23-020131-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-020131-xbrl.zip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